SNTI

$0.18-5.37%visit website

Senti Biosciences, Inc.

Market Cap

$6M

Live price × SEC shares (Jul 31, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

2.30

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

—

Mkt cap / TTM revenue

P/B

N/M

TTM to Jun 2026 · negative equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue			16.0	17.0
Research & development	10,516	7,760	5,281	7,767	31,324
Total operating expenses	16,948	18,658	4,632	14,506	54,744
Operating income	(16,948)	(18,636)	(4,616)	(14,489)	(54,689)
Income tax	0.00	0.00	0.00	0.00	0.00
Net income	(18,126)	(14,467)	(4,221)	(12,750)	(49,564)
EPS (basic) ($)	(0.69)		(0.14)	(0.41)	—
EPS (diluted) ($)	(0.69)		(0.14)	(0.41)	—
Weighted avg. shares (basic)	26,228		30,972	31,145
Weighted avg. shares (diluted)	26,228		30,972	31,145

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 14, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 17 more quarters, back to Q2 FY2021, with Tormere Pro.

Corporate Events (8-K)

2 filings in 12 months · 1 with priority itemsFull history →

Filed	Items	Filing
Oct 27, 2026 accepted 4:38 PM ET	5.02Officer / director change8.01Other events	Document SEC ↗
Oct 26, 2026 accepted 4:17 PM ET	1.01Material agreement1.02Agreement terminated2.01Acquisition / disposition3.02Unregistered equity sale	Document SEC ↗